Archive \ Volume.12 2021 Issue 1

Pharmaceutical marketing strategies’ influence on physician’s prescription behavior

Abbas N. Albarq , Amal k. Suleiman
Abstract

Introduction: Pharmaceutical marketing practices are one of the main reasons that massively influence the physician’s prescribing behavior. This issue has been hardly explored in very little studies that investigated the impact of pharmaceutical marketing strategies on prescribing patterns in developing countries and Middle Eastern countries. Objective: This paper aims to explore the impact of pharmaceutical marketing practices on the medication recommendation of physicians in Jordan. Methods: The convenience sampling method was used to attain the objectives of the study. The duration of the study was from 1st August 2019 till 28th February 2020. A self-administrative questionnaire was used upon receiving ethical approval, verbal consent was also taken from the participant. SPSS version 20 was used to perform statistical analysis. Results: The response rate to the survey was 80.9%. Then the processed data inferred the result, which was evaluated based on a seven-point Likert Scale. From the observations, one can conclude that pharmaceutical marketing practices have tremendous power over manipulating the prescription behavior of the doctors. This paper evaluates the effectiveness of various promotional tools employed by the markets to achieve their goal. After scrutinizing the whole report, the “public relations” strategy was found to be profound of all. Whereas advertisements using print media caught the least attention. Conclusion: The findings of the present study proved to be instrumental in serving as the first step in the imminent direction of merging this paper with the previous literature. From a managerial perspective, this research can benefit various marketers to evolve novel, refined strategies to influence the Jordanian physicians to boost up their ratings.



How to cite:
Vancouver
Albarq A N, Suleiman A K. Pharmaceutical marketing strategies’ influence on physician’s prescription behavior. Arch. Pharm. Pract. 2021;12(1):7-12. https://doi.org/10.51847/Z1e2zxY21k
APA
Albarq, A. N., & Suleiman, A. K. (2021). Pharmaceutical marketing strategies’ influence on physician’s prescription behavior. Archives Of Pharmacy Practice, 12(1),7-12. https://doi.org/10.51847/Z1e2zxY21k

Download Citation
References
  1. Campbell, E.G., et al., A national survey of physician–industry relationships. New England Journal of Medicine, 2007. 356(17): p. 1742-1750.
  2. James, C.D., et al., An unhealthy public-private tension: pharmacy ownership, prescribing, and spending in the Philippines. Health Affairs, 2009. 28(4): p. 1022-1033.
  3. Haider S, Nisar QA, Baig F, Azeem M. Dark Side of Leadership: Employees' Job Stress & Deviant Behaviors in Pharmaceutical Industry. Int. J. Pharm. Res. Allied Sci. 2018;7(2):125-38.
  4. Ruslan S. Fyl, Svitlana P. Fyl, Iryna V. Аlekseenko, Maryna P. Kobets, Iryna H. Lubenets. Legal regulation of the EU pharmaceutical market and the possibility of implementing the European experience in Ukraine. J Adv Pharm Edu Res. 2019;9(4):1-8.
  5. Fauziah F, Surachman E, Muhtadi A. Integration of service quality and quality function deployment as an effort of pharmaceutical service improvement on outpatient in a referral Hospital Karawang Indonesia. J Adv Pharm Edu Res. 2019;9(2):13-23.
  6. Biswas, K. and U. Ferdousy, Influence of pharmaceutical marketing on prescription behavior of physicians: a cross-sectional study in Bangladesh. Journal of Accounting & Marketing, 201 5(2): p. 1-4.
  7. Alshehry YA, Ghonaim HM, Khalid MS. Comparative Evaluation of the Analgesic Effect of Brand and Generics of Meloxicam tablets Available in markets. Int. J. Pharm. Phytopharm. Res. 2019;9(3):73-9.
  8. Khazzaka, M., Pharmaceutical marketing strategies’ influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples. BMC health services research, 2019. 19(1): p. 80.
  9. Blumenthal, D., Doctors and drug companies. American Journal of Ophthalmology, 2005. 139(3): p. 583.
  10. Lidstone, J. and J. MacLennan, Marketing planning for the pharmaceutical industry. 1999: Gower Publishing, Ltd.
  11. Bagozzi, R.P., M. Gopinath, and P.U. Nyer, The role of emotions in marketing. Journal of the academy of marketing science, 1999. 27(2): p. 184-206.
  12. Lam, M.D., A $20 billion bill and plenty of change. Pharmaceutical Executive Sept, 2004. 1.
  13. Smith, M.C., Pharmaceutical marketing: strategy and cases. 1991: CRC Press.
  14. Marco, C.A., et al., Gifts to physicians from the pharmaceutical industry: an ethical analysis. Annals of emergency medicine, 2006. 48(5): p. 513-521.
  15. Chew, L.D., et al., A physician survey of the effect of drug sample availability on physicians’ behavior. Journal of General Internal Medicine, 2000. 15(7): p. 478-483.
  16. Ghaith, A., H. Aldmour, and H. Alabbadi, Investigating the effect of pharmaceutical companies’ gifts on doctors’ prescribing behavior in Jordan. European Journal of Social Sciences, 2013. 36(4): p. 528-536.
  17. Lexchin, J., Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ: Canadian Medical Association Journal, 1993. 149(10): p. 1401.
  18. Gönül, F.F., et al., Promotion of prescription drugs and its impact on physicians' choice behavior. Journal of Marketing, 2001. 65(3): p. 79-90.
  19. Lexchin, J., What information do physicians receive from pharmaceutical representatives? Canadian Family Physician, 1997. 43: p. 941.
  20. Manchanda, P. and E. Honka, The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J. Health Pol'y L. & Ethics, 2005. 5: p. 785.
  21. Nair, H.S., P. Manchanda, and T. Bhatia, Asymmetric social interactions in physician prescription behavior: The role of opinion leaders. Journal of Marketing Research, 2010. 47(5): p. 883-895.
  22. Lexchin, J., Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis. Journal of pharmaceutical policy and practice, 2018. 11(1): p. 5.
  23. Zachary Brennan, Do Biopharma Companies Really Spend More on Marketing Than R&D?, in Regulatory Focus. 2019, Regulatory Affairs Professionals Society (RAPS).
  24. Kassirer, J.P., The 21st Century Cures Potpourri: Was It Worth the Price? American journal of law & medicine, 2018. 44(2-3): p. 157-160.
  25. Baethge, C., Transparent texts: authors of scientific articles often have conflicts of interest. It is important for these to be communicated transparently to the readers. Deutsches Arzteblatt International, 2008. 105(40): p. 675.
  26. Bloor, K. and N. Freemantle, Fortnightly Review: Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. BMJ, 1996. 312(7045): p. 1525-1527.
  27. Pitt, L. and D. Nel, Pharmaceutical promotion tools—Their relative importance. European Journal of Marketing, 1988;22(5):7-14.
  28. Wazana, A., Physicians and the pharmaceutical industry: is a gift ever just a gift? Jama, 2000. 283(3): p. 373-380.
  29. Kotler, P., Marketing Management Prentice Hall of India Pvt. Ltd, New Delhi, 1999.
  30. Liu, S.S., A comparison of pharmaceutical promotional tactics between Hong Kong and China. Journal of Business & Industrial Marketing, 1995;10(1):34-43.
  31. Nishtar, S., et al., Health reform in Pakistan: a call to action. The Lancet, 2013. 381(9885): p. 2291-2297.
  32. Albarq, A. N., & Al Doghan, M. Electronic Word-Of-Mouth versus Word-Of-Mouth in the Field Of Consumer Behavior: A Literature Review, 2020. 7(14):646-645.
  33. Baghdadi-Sabeti, G. and F. Serhan, WHO Good Governance for Medicines programme: an innovative approach to prevent corruption in the pharmaceutical sector. Geneva: World Health Organization, 2010.